PLSE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pulse Biosciences Inc (PLSE) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has potential catalysts in its pipeline, such as the nPulse Cardiac Catheter program and positive feasibility study results, the financial performance remains weak with declining net income and EPS. Insider selling and lack of significant hedge fund activity further weaken the case for immediate investment. A hold position is recommended until more concrete financial improvements or broader adoption of its technology are observed.
The technical indicators are mixed. The MACD is positive and expanding, suggesting bullish momentum. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the pre-market price is near the R1 resistance level of 22.643. However, the RSI of 77.685 is in the neutral zone, not providing a clear signal. The stock's historical trend suggests limited short-term upside potential.
Positive feasibility study results for the nPulse Cardiac Catheter program, showing high efficacy in treating Atrial Fibrillation.
FDA approval to commence pivotal IDE study for paroxysmal-AF.
Plans to present new clinical data at the 2026 Heart Rhythm Conference.
Insiders are selling heavily, with a 3340.02% increase in selling activity over the last month.
Weak financial performance in Q4 2025, with declining net income (-10.07% YoY) and EPS (-16.13% YoY).
Lack of significant hedge fund activity and no recent congress trading data.
In Q4 2025, revenue remained flat at $264,000, while net income dropped to -$17.43M (-10.07% YoY) and EPS fell to -$0.26 (-16.13% YoY). Gross margin remained unchanged at 1.52%. The financials indicate weak profitability and growth.
Analysts are optimistic about PLSE, with Oppenheimer and Mizuho raising their price targets to $30 and maintaining Outperform ratings. Analysts highlight strong technology adoption potential and positive feasibility study results. However, they caution that larger trials are needed to confirm efficacy.
